[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100582146":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":12,"centralContacts":17,"locations":23,"responsibleParty":35,"collaborators":37,"id":39,"slug":40,"hasResults":41,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":7,"eligibilityCriteria":45,"healthyVolunteers":41,"sex":46,"minAge":47,"maxAge":7,"enrollmentInfo":48,"targetDuration":7,"studyType":51,"phases":7,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":25,"whyStopped":7,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},{"fullName":5,"class":6},"Guangzhou Jiayin Biotech Ltd","INDUSTRY",null,[9],{"type":10,"name":11,"description":11,"armGroupLabels":7,"otherNames":7},"OTHER","No intervention, only for observational studies",[13],{"name":14,"affiliation":15,"role":16},"Mingwei ZHAO, PhD","Peking University People's Hospital","PRINCIPAL_INVESTIGATOR",[18],{"name":19,"role":20,"phone":21,"phoneExt":7,"email":22},"Sara Yang, MD","CONTACT","+86 13957164092","sarayang@exegenesisbio.com",[24],{"facility":15,"status":25,"city":26,"state":7,"zip":7,"country":27,"countryCode":28,"cosmosGeoPoint":29,"geoPoint":34,"contacts":7},"RECRUITING","Beijing","China","CN",{"type":30,"coordinates":31},"Point",[32,33],116.39723,39.9075,{"lat":33,"lon":32},{"type":36,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[38],{"name":15,"class":10},"100582146","a-long-term-follow-up-study-of-exg102-031-in-participants-with-wamd-100582146",false,"NCT06859515","A Long-term Follow up Study of EXG102-031 in Participants With wAMD","A Long-term Follow-up Study to Evaluate the Injection of EXG102-031 Ophthalmic Injection in Participants With Wet Age-related Macular Degeneration (wAMD).","Inclusion Criteria:\n\n1. Previously received treatment with EXG102-031 in the study (EXG102-031-111);\n2. Paticipantes are informed consent and willingness to follow protocol procedures.\n\nExclusion Criteria:\n\n1\\. Paticipantes are unwilling or unable to participate in long-term follow-up","ALL","50 Years",{"count":49,"type":50},42,"ESTIMATED","OBSERVATIONAL","This is a long-term, safety and efficacy follow-up study of patients in the EXG102-031-111 gene therapy clinical trial for wAMD. Patients will complete visits from the parent study, and then into this long-term follow-up study for continuous safety monitoring for up to 5 years.",[54],"Wet Age-related Macular Degeneration",[56,57],"AAV","wAMD","2025-08-14",{"date":60,"type":61},"2025-08-15","ACTUAL",{"date":63,"type":61},"2025-03-13",{"date":65,"type":50},"2030-12-01",{"name":5,"class":6},1]